Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) FCF Margin: 2017-2025

Historic FCF Margin for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to 17.76%.

  • Puma Biotechnology's FCF Margin rose 408.00% to 17.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.23%, marking a year-over-year increase of 640.00%. This contributed to the annual value of 16.86% for FY2024, which is 546.00% up from last year.
  • As of Q3 2025, Puma Biotechnology's FCF Margin stood at 17.76%, which was down 33.81% from 26.83% recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's FCF Margin peaked at 26.83% during Q2 2025, and registered a low of -58.80% during Q1 2022.
  • For the 3-year period, Puma Biotechnology's FCF Margin averaged around 14.96%, with its median value being 14.42% (2023).
  • As far as peak fluctuations go, Puma Biotechnology's FCF Margin slumped by 7,476bps in 2022, and later surged by 6,381bps in 2023.
  • Quarterly analysis of 5 years shows Puma Biotechnology's FCF Margin stood at -9.82% in 2021, then soared by 2,657bps to 16.75% in 2022, then crashed by 233bps to 14.42% in 2023, then surged by 1,197bps to 26.39% in 2024, then skyrocketed by 408bps to 17.76% in 2025.
  • Its last three reported values are 17.76% in Q3 2025, 26.83% for Q2 2025, and 7.72% during Q1 2025.